Scholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug
Scholar Rock announced it would remove Novo Nordisk's Indiana manufacturing facility from its FDA approval application for apitegromab, a drug targeting rare neuromuscular disease. The FDA had previously declined to approve the drug due to issues identified during a routine inspection of the fill-finish facility. The move is intended to clear a path toward securing regulatory approval for the treatment.
The Atomic take
This is a manufacturing problem, not a science problem, which means apitegromab's clinical case for muscle preservation stayed intact even as the FDA rejected the filing over a third-party fill-finish site. By excising the Novo Nordisk Indiana facility rather than waiting for it to pass reinspection, Scholar Rock is betting it can requalify an alternate finisher fast enough to keep the approval timeline from slipping badly. Watch whether the FDA accepts the amended application without demanding fresh manufacturing data, and how quickly the company names the replacement site.
Read the full story at Reuters →Know where humanity is headed.
Five forces, one investment thesis a day. Free, every weekday morning.
Get The Atomic Five